<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168329">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906035</url>
  </required_header>
  <id_info>
    <org_study_id>706469</org_study_id>
    <secondary_id>0821</secondary_id>
    <nct_id>NCT00906035</nct_id>
  </id_info>
  <brief_title>The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)</brief_title>
  <official_title>The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will evaluate the effects of aspirin and dipyridamole alone and in
      combination on the blood flow in the vessels of the legs. We will examine how these
      medications are able to inhibit the clotting of platelets in the vessels of patients with
      PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that
      have the ability to adhere to each other to form clots.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dipyridamole has been reformulated to guarantee systemic bioavailability and steady state
      levels compatible with inhibition of platelet aggregation ex vivo (1). This newly formulated
      dipyridamole has been shown to roughly equal in efficacy to low dose aspirin in the
      secondary prevention of stroke and the drug combination seems roughly additive (2). The
      present study is designed to explore two potential mechanisms which have been linked to
      dipyridamole action on the vessel wall; modulation of vascular eicosanoid generation and
      prevention of oxidant stress (3). We shall address the hypothesis that dipyridamole affects
      these systems in patients with PAD. These individuals have disordered platelet-vascular
      interactions, as reflected by increased generation of thromboxane, an index of platelet
      activation and of prostacyclin, probably a homeostatic response to traumatic and chemical
      stimulation of the endothelium (4,5). Furthermore, we shall assess the functional
      consequences of dipyridamole action, alone and in combination with aspirin compared with
      aspirin alone on local measurements of flow and oxygenation, including exercise tolerance,
      Doppler Ultrasound and Near Infrared Spectroscopy (NIRS). Lipid peroxidation will be
      quantified based on mass spectrometric analysis of the major urinary isoprostane,
      8,12-iso-iPF2a-VI (6,7).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty finding subjects who met the inclusion/exclusion criteria.
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The present study is designed to explore two potential mechanisms which have been linked to dipyridamole action on the vessel wall; modulation of vascular eicosanoid generation and prevention of oxidant stress.</measure>
    <time_frame>Predose and dosing days 30, 90 and 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the functional consequences of dipyridamole action, alone and in combination with aspirin compared with aspirin alone on local measurements of flow and oxygenation.</measure>
    <time_frame>Predose and dosing days 30, 90 and 180.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Dipyridamole 200mg and Aspirin 25mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dipyridamole 200 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 25 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole 200mg and Aspirin 25mg bid:</intervention_name>
    <description>All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.</description>
    <arm_group_label>Dipyridamole 200mg and Aspirin 25mg bid</arm_group_label>
    <other_name>Persantine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole 200 mg bid</intervention_name>
    <description>All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.</description>
    <arm_group_label>Dipyridamole 200 mg bid</arm_group_label>
    <other_name>Persantine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 25 mg bid</intervention_name>
    <description>All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.</description>
    <arm_group_label>Aspirin 25 mg bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 - 79

          -  Women of child bearing potential using a medically acceptable method of birth control
             (oral/transdermal/vaginal hormonal contraception, depo-provera injection, IUD, condom
             with spermicide, progestin implant, tubal ligation, oophorectomy, TAH) or abstinence.

          -  Capacity for giving written consent

          -  Diagnosis of PAD by:

               -  previous angiogram (&gt;0.5 stenosis of a peripheral artery)

               -  ankle-brachial index (ABI) of systolic pressure &lt;0.80

               -  previous peripheral revascularization

          -  Smokers who smoke &lt; 10 cigarettes / day

        Exclusion Criteria:

          -  Female subjects who are pregnant or nursing a child.

          -  Prior bleeding event related to drug therapy

          -  History of gastrointestinal ulceration

          -  History of known dipyridamole and/or aspirin allergy or intolerance

          -  History of coagulation, bleeding or blood disorders.

          -  Recent history of myocardial infarction or stroke in the previous 6 months

          -  Resting blood pressure of &lt;110mmHg systolic or &lt;60mmHg diastolic or of &gt;165mmHg
             systolic or &gt;95mmHg diastolic

          -  Patients with active infection as documented by abnormal laboratory tests at screen

          -  Concomitant serious illness, such as cancer, as per the principal investigator's
             discretion

          -  Current use of steroids for a chronic disease process

          -  Presence of ischemic leg ulcers

          -  History of contact allergies to the metal leads of the NIRS

          -  History of drug or alcohol abuse within the last 6 months.

          -  Subject who has received an experimental drug and/or used an experimental device
             within 30 days of screening.

          -  Subject who has donated â‰¥ one pint of blood within 8 weeks prior to screen.

          -  Use of aspirin for 2 weeks prior to the study

          -  Use of any other NSAID or COX-inhibitor for one week prior to the start of the study

          -  Use of any antioxidant vitamin for 2 weeks prior to the start of the study

          -  Use of plavix, pletal or trental for one week prior to the start of the study

          -  Use of acetaminophen for one week prior to each study visit

          -  Use of alcohol, caffeine or high fat foods for 24 hours prior to each study visit

          -  Has smoked any cigarettes for 24 hours prior to each study visit

          -  Platelet aggregation blood test less than 60 percent at Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garret A FitzGerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emile R Mohler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>January 31, 2013</lastchanged_date>
  <firstreceived_date>May 20, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>PAD</keyword>
  <keyword>Claudication</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
